Effects of pasireotide (SOM230) on protein turnover and p70S6 kinase-S6 ribosomal protein signaling pathway in rat skeletal muscle cells
- 142 Downloads
The multiligand somatostatin (SS-14) analog pasireotide (SOM230) has been approved to treat patients harboring ACTH-secreting pituitary adenomas . The higher binding affinity of pasireotide for the sst5 receptor subtype compared to the first generation analogs, octreotide and lanreotide [2, 3], joint to a functional selectivity of distinct SS-14 analogs at sst2 receptor [4, 5], suggest to explore its potential effects on extra-pituitary tissues. Indeed, SS-14 receptor subtypes (sst1–5) are heterogeneously expressed in different tissues . There is evidence that SS-14 is transiently expressed in motoneurons during early postnatal development in the rat and the expression of sst2, sst3, and sst4 receptor subtypes in rat skeletal muscle decreases progressively during development . To our knowledge, the hypothesis that stable SS-14 analogs may exert some direct effects in skeletal muscle cells has not been tested yet. These effects, if any, would certainly be of interest as to the...
This study was supported by local funds (2012–2013) from the University of Brescia to G.T. and by a grant from Novartis Farma Spa (Origgio, Italy) to the Center for Research in Osteoporosis and Bone Metabolism, University of Brescia (A.G.). Funding sources have not had any role in study design and interpretation of data, except for the personal contribution of the author M.S. which is an employee of Novartis Farma.
Compliance with ethical standards
Conflict of interest
G.T., L.F., declare that they have no conflict of interest. M.S. is employed by Novartis Farma SpA (Origgio, Italy). A.G. has received consulting and lecture fees form Ipsen, Novartis and Pfeizer.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 8.G. Tulipano, L. Faggi, A. Cacciamali, M. Spinello, D. Cocchi, A. Giustina, Role of AMP- activated protein kinase activators in antiproliferative multi-drug pituitary tumor therapy: effects of combined treatments with compounds affecting the mTOR-p70S6 kinase axis in cultured pituitary tumor cells. J. Neuroendocrinol. 27, 20–32 (2015)CrossRefGoogle Scholar